Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21021800 | 0.94 | MEN1 (0.43) | MAPTMEN1KMT2AL3MBTL1CARM1 | |
| SCHEMBL21020774 | 0.92 | CARM1 (0.43) | MAPTMEN1KMT2AL3MBTL1CARM1 | |
| SCHEMBL21020837 | 0.87 | MEN1 (0.43) | MAPTMEN1KMT2AL3MBTL1CARM1 | |
| SCHEMBL21021406 | 0.86 | HDAC1 (0.44) | MAPTHDAC1HDAC6LMNAPRMT5 | |
| SCHEMBL21020889 | 0.86 | MEN1 (0.39) | MAPTMEN1KMT2AL3MBTL1CARM1 | |
| SCHEMBL21020840 | 0.86 | MEN1 (0.37) | MAPTMEN1KMT2AL3MBTL1CARM1 | |
| SCHEMBL21020899 | 0.85 | PSMB5 (0.40) | MAPTMEN1KMT2AL3MBTL1CARM1 | |
| SCHEMBL21020216 | 0.84 | DRD2 (0.39) | MAPTMEN1KMT2AL3MBTL1CARM1 | |
| SCHEMBL21020197 | 0.84 | ACACB (0.44) | MEN1KMT2AL3MBTL1PRMT5WDR77 | |
| SCHEMBL21020893 | 0.83 | CARM1 (0.34) | MAPTMEN1KMT2AL3MBTL1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186548-B2 | Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | U.S. DEPARTMENT OF ENERGY | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | ACHE, BCHE, CHAT | MAPT 1292/4885MEN1 4112/4885KMT2A 1168/4885 |
| US-11186548-B2 | Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them | ACHE, BCHE, CHAT | MAPT 1292/4885MEN1 4112/4885KMT2A 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.